Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 06, 2016 4:05 PM ET

Pharmaceuticals

Company Overview of Corium International, Inc.

Company Overview

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; Crest Whitestrips for teeth whitening. The company’s products under pipeline comprise AG200-15, a combination hormonal contraceptive patch, that is in phase III clinical trial to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed phase II a clinical ...

235 Constitution Drive

Menlo Park, CA 94025

United States

Founded in 1995

247 Employees

Phone:

650-298-8255

Fax:

650-298-8012

Key Executives for Corium International, Inc.

Chief Executive Officer, President and Director
Age: 63
Total Annual Compensation: $447.3K
Chief Financial Officer
Age: 53
Total Annual Compensation: $356.8K
Chief Technology Officer and Vice President of Research & Development
Age: 51
Total Annual Compensation: $312.7K
Compensation as of Fiscal Year 2015.

Corium International, Inc. Key Developments

Corium International Files Shelf Registration; Mulls Acquisitions

Corium International, Inc. (NasdaqGM:CORI) filed a Shelf Registration in the amount of $76.42 million. The company intends to use the net proceeds from the sale of securities under this prospectus for general corporate purposes, which may include funding research and development, increasing our working capital, reducing indebtedness, acquisitions or investments in businesses, products or technologies that are complementary to our own and capital expenditures.

Corium International, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2015; Provides Earnings Guidance for the Year 2016

Corium International, Inc. announced unaudited earnings results for the fourth quarter and full year ended September 30, 2015. For the quarter, the company reported total revenues of $9,266,000 against $11,072,000 a year ago. Loss from operations was $6,690,000 against $4,797,000 a year ago. Loss before income taxes was $8,634,000 against $6,366,000 a year ago. Basic and diluted net loss attributable to common stockholders was $8,635,000 against $6,367,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.42 against $0.35 a year ago. The decrease in total revenues primarily resulted from declining product revenues from Fentanyl TDS (marketed by Par Pharmaceutical) and Clonidine TDS (marketed by Teva Pharmaceuticals), partially offset by growth in contract research and development revenues. Product revenues for the quarter were $6.0 million compared with $9.0 million in 2014.   For the year, the company reported total revenues of $40,921,000 against $42,440,000 a year ago. Loss from operations was $21,024,000 against $10,050,000 a year ago. Loss before income taxes was $28,447,000 against $9,911,000 a year ago. Basic and diluted net loss attributable to common stockholders was $28,450,000 against $9,912,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $1.52 against $0.99 a year ago. Revenue was primarily due to expected declines in product revenues from both Clonidine TDS (marketed by Teva Pharmaceuticals) and Fentanyl TDS (marketed by Par Pharmaceutical), partially offset by an increase in contract research and development revenues from co-development programs and new partner-funded programs.  In addition, revenues for the fiscal year ended September 30, 2014, included recognition of $1.8 million in non-cash product revenue that had been previously deferred since 2007.  The recognition of this revenue related to the expiration of a contractual liability, and does not have an impact on revenues after fiscal 2014. Product revenues for the year were $26.5 million compared with $32.2 million in 2014. The company currently anticipates that 2016 revenues could be between 80% and 120% of 2015 revenues. The company expects R&D expenses and G&A expenses continue to increase.

Corium International, Inc. to Report Q4, 2015 Results on Nov 12, 2015

Corium International, Inc. announced that they will report Q4, 2015 results at 5:00 PM, Eastern Standard Time on Nov 12, 2015

Similar Private Companies By Industry

Company Name Region
GlobeRx.com United States
AvMax, Inc. United States
Toyo Bio-Pharma, Inc. United States
The Clinical Research Center United States
Xstelos Holdings, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Corium International, Inc., please visit www.coriumgroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.